Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
63%(5 trials)

Phase Distribution

Ph phase_1
1
10%
Ph phase_4
3
30%
Ph phase_3
2
20%
Ph not_applicable
1
10%
Ph phase_2
2
20%

Phase Distribution

1

Early Stage

2

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

8 of 8 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(8)
Other(2)

Detailed Status

Completed8
unknown2

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 32 (22.2%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

completed880%
unknown220%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure

NCT06003972
unknownphase_1

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

NCT03982212
completedphase_4

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

NCT02499900
completedphase_4

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

NCT00176592
completednot_applicable

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

NCT00937157
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT06003972Phase 2

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure

Completed
NCT03982212Phase 1

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Unknown
NCT02499900Phase 4

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Completed
NCT00176592Phase 4

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI

Completed
NCT00937157Not Applicable

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)

Completed
NCT00078338Phase 4

Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis

Completed
NCT00451204Phase 2

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Completed
NCT00490906

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis

Completed
NCT01936129Phase 3

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure

Unknown
NCT00099502Phase 3

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10